Discover investment opportunities in Besteuropeanstocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Besteuropeanstocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Besteuropeanstocks using our Smart AI Filter.
10 stocks found for "Besteuropeanstocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.67 | ±23.5% | 9.8 | 18.34% | |||
0.56 | ±28.3% | 8.2 | 3.67% | |||
0.45 | ±20.5% | 12.7 | 3.02% | |||
0.46 | ±18.0% | 32.0 | 2.08% | |||
0.49 | ±18.7% | 14.5 | 12.70% | |||
0.64 | ±25.1% | 45.0 | 3.12% | |||
0.28 | ±18.2% | 7.8 | 2.73% | |||
1.13 | ±43.6% | 29.8 | 1.05% | |||
0.71 | ±23.6% | 8.2 | 6.21% | |||
0.94 | ±29.2% | 15.6 | 0.78% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
SAP will invest more than 20 billion euros into its sovereign cloud capabilities in Europe over the next decade, the company announced Tuesday. The aim is to ensure customer data is stored within the EU to maintain compliance with regional data protection regulations like GDPR.
Read morePresident Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read morePresident Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Read moreQ: What factors contribute to the investment appeal of ASML Holdings in the European tech sector?
A: ASML Holdings, a leader in the semiconductor equipment market, benefits from cutting-edge technology and a strong global demand for chips. The company's market dominance and robust intellectual property portfolio make it appealing to investors seeking growth in the European tech sector.
Q: How does SAP's business model support its growth prospects in the software industry?
A: SAP's subscription-based software model provides recurring revenue streams and robust customer relationships. Expansion into cloud services aligns with digital transformation trends, supporting long-term growth prospects in the competitive software market.
Q: What should investors know about Sanofi's dividend history?
A: Sanofi, a French pharmaceutical giant, has a stable history of dividend payments. Some investors consider its consistent payouts attractive, though it's crucial to analyze its financial health and R&D pipeline to assess future dividend sustainability.
Q: How does Novo Nordisk's focus on diabetes care impact its investment potential?
A: Novo Nordisk's specialization in diabetes care positions it well in a growing market segment. The focus provides a competitive edge and potential for stable revenues, appealing to investors seeking exposure to the healthcare industry.
Q: What sector-specific risks should be considered when investing in CRH plc, a building materials supplier?
A: CRH plc faces risks related to economic cycles, particularly in construction demand fluctuations. Regulatory changes and sustainability pressures also pose challenges in the building materials sector.
Q: How has AstraZeneca's performance in vaccine development affected its market perception?
A: AstraZeneca's COVID-19 vaccine efforts have bolstered its reputation in the biotech arena. This may suggest increased investor interest; however, scrutiny over safety and efficacy pose ongoing challenges.